• Ji Eun Kim and Hea Rim Chun.
• Department of Anesthesiology and Pain Medicine, Soonchunhyang University Hospital Cheonan, Dongnam-gu, Cheonan, Chungcheongnam-do, Korea.
• Medicine (Baltimore). 2017 Mar 1; 96 (13): e6456.

IntroductionAnesthetic management of patients with Duchenne muscular dystrophy (DMD) is complicated because these patients are more sensitive to nondepolarizing neuromuscular blocking agents (NMBAs) and are vulnerable to postoperative complications, such as postoperative residual curarization and respiratory failure. Sugammadex is a new reversal agent for aminosteroidal NMBAs, but its safety in children is controversial.Clinical FeaturesAn 11-year-old boy with DMD underwent general anesthesia for a percutaneous nephrolithotomy. We used rocuronium bromide and sugammadex to reverse the deep neuromuscular block. Reversal of neuromuscular block was done 15 minutes after administration of 2 mg/kg of sugammadex. The patient's recovery from anesthesia was uneventful, and he was discharged to the postoperative recovery ward.ConclusionA delayed recovery was achieved, but no adverse events were observed, such as recurarization or hypersensitivity to sugammadex. We report safe use of 2 mg/kg of sugammadex to reverse a deep neuromuscular block in a child with DMD.

16 keywords...

hide…